Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies

NCT06527404 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06527404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06527404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Terminated
Start date
July 18, 2024
Completion date
June 25, 2026
Enrollment
469 (actual)
Sites
192

Conditions

As the registry lists them; a condition with its own page is linked.

prurigo nodularis